Health Care [ 1/12 ] | Pharmaceuticals [ 10/73 ]
NASDAQ | Common Stock
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 25 | 0.04 Increased by +173.73% | -0.13 Increased by +132.58% |
| Aug 4, 25 | -0.08 Increased by +69.93% | 0.67 Decreased by -112.51% |
| May 12, 25 | -0.17 Increased by +27.75% | -0.09 Decreased by -92.67% |
| Feb 24, 25 | -0.05 Increased by +70.53% | -0.08 Increased by +39.86% |
| Nov 12, 24 | -0.06 Increased by +65.29% | -0.23 Increased by +74.35% |
| Aug 5, 24 | -0.28 Increased by 0.00% | -0.21 Decreased by -33.33% |
| May 13, 24 | -0.24 Increased by +31.43% | -0.25 Increased by +4.00% |
| Feb 26, 24 | -0.17 Decreased by -13.33% | -0.15 Decreased by -13.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 19.99 M Increased by +18.51% | 3.62 M Increased by +128.47% | Increased by +18.08% Increased by +124.02% |
| Jun 30, 25 | 26.20 M Increased by +83.75% | 54.84 M Increased by +431.75% | Increased by +209.33% Increased by +280.55% |
| Mar 31, 25 | 15.39 M Increased by +6.10% | -13.58 M Decreased by -16.42% | Decreased by -88.24% Decreased by -9.72% |
| Dec 31, 24 | 18.75 M Increased by +6.77% | -15.53 M Decreased by -82.46% | Decreased by -82.79% Decreased by -70.89% |
| Sep 30, 24 | 16.87 M Increased by +7.49% | -12.70 M Decreased by -41.88% | Decreased by -75.28% Decreased by -31.99% |
| Jun 30, 24 | 14.26 M Increased by +3.69% | -16.53 M Decreased by -5.65% | Decreased by -115.94% Decreased by -1.89% |
| Mar 31, 24 | 14.50 M Increased by +39.22% | -11.66 M Increased by +47.19% | Decreased by -80.42% Increased by +62.07% |
| Dec 31, 23 | 17.57 M Increased by +19.91% | -8.51 M Increased by +17.87% | Decreased by -48.45% Increased by +31.51% |